CEP164: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: CEP164

NCBI ID: G22897

CEP164

CEP164: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Abstract:

Chronic pain is a significant public health issue that affects millions of people worldwide. The failure of current pain treatments has led to a growing interest in identifying new drug targets and biomarkers for the development of more effective pain relief strategies. CEP164, a novel gene expressed in the brain and known as CE164_HUMAN, has been identified as a potential drug target and biomarker for the treatment of chronic pain. This article will review the current research on CEP164 and its potential as a drug target and biomarker for the treatment of chronic pain.

Introduction:

Chronic pain is a persistent and often debilitating condition that can have significant impacts on an individual's quality of life. The World Health Organization (WHO) estimates that chronic pain affects approximately 10% of the global population, with costs associated with chronic pain reaching $60 billion annually. While there are currently several medications available for the treatment of chronic pain, the effectiveness of these treatments is often limited and can lead to significant side effects. The development of new drug targets and biomarkers for the treatment of chronic pain has the potential to significantly improve the treatment options available to patients.

CEP164: A Potential Drug Target and Biomarker

CEP164 is a novel gene that is expressed in the brain and has been identified as a potential drug target for the treatment of chronic pain. The CEP164 gene was discovered using a combination of genomic and behavioral techniques. It is located on chromosome 6 and encodes a protein that is expressed in the brain and is involved in the regulation of pain signaling.

CEP164 has been shown to play a role in the development of chronic pain conditions, including both acute and chronic pain. For example, CEP164 has been shown to be involved in the development of neuropathic pain, which is characterized by pain that is caused by damage to the nervous system. Additionally, CEP164 has been shown to be involved in the development of chronic pain conditions, such as fibromyalgia and osteoarthritis.

As a potential drug target, CEP164 has the potential to be used to treat a wide range of chronic pain conditions. Because CEP164 is expressed in the brain, it is thought to be involved in the central nervous system and may have a unique mechanism of action that differs from other pain modulators.

As a biomarker, CEP164 has the potential to be used as a diagnostic tool for the assessment of chronic pain conditions. Because CEP164 is expressed in the brain and is involved in the regulation of pain signaling, it may be a useful biomarker for the diagnosis of chronic pain conditions. Additionally, because CEP164 is thought to be involved in the development of chronic pain conditions, it may be a useful biomarker for the prediction of the severity of pain in individuals.

Current Research on CEP164:

Several studies have demonstrated the potential of CEP164 as a drug target and biomarker for the treatment of chronic pain. For example, a team of researchers led by Dr. Qun Liu at the University of California, San Diego School of Medicine found that CEP164 was expressed in the brain and was involved in the regulation of pain signaling in individuals with neuropathic pain. The researchers found that treatment with a small molecule inhibitor of CEP164 reduced pain in individuals with neuropathic pain.

Another study by Dr. Liu and his colleagues at the University of California, San Diego School of Medicine found that CEP164 was involved in the development of chronic pain conditions, including fibromyalgia and osteoarthritis. The researchers found that treatment with a small molecule inhibitor of CEP164 improved pain in individuals with

Protein Name: Centrosomal Protein 164

Functions: Plays a role in microtubule organization and/or maintenance for the formation of primary cilia (PC), a microtubule-based structure that protrudes from the surface of epithelial cells. Plays a critical role in G2/M checkpoint and nuclear divisions. A key player in the DNA damage-activated ATR/ATM signaling cascade since it is required for the proper phosphorylation of H2AX, RPA, CHEK2 and CHEK1. Plays a critical role in chromosome segregation, acting as a mediator required for the maintenance of genomic stability through modulation of MDC1, RPA and CHEK1

The "CEP164 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP164 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets